Related Experiment Videos
Clinical heterogeneity: responders to cholinergic therapy
1Academic Department of Old Age Psychiatry, St. Mary's Hospital Medical School, St. Charles Hospital, London, England.
Alzheimer Disease and Associated Disorders
|January 1, 1995
Summary
Identifying Alzheimer disease patients who respond to cholinergic therapy is crucial. Adequate dosing is key before concluding non-response to Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Alzheimer disease (AD) is a heterogeneous neurodegenerative disorder.
- Patient heterogeneity impacts treatment response to therapies like cholinesterase inhibitors.
- Identifying responders to cholinergic therapy is vital for effective AD management.
Purpose of the Study:
- To review patient and trial heterogeneity in Alzheimer disease research.
- To explore potential predictors of response to cholinergic therapy in AD.
- To assess the current evidence for identifying responders to AD treatments.
Main Methods:
- Review of existing literature on Alzheimer disease heterogeneity and treatment response.
- Summary of findings from small studies investigating potential response predictors.
- Analysis of predictors including psychometric tests, physiological measures, and neuroimaging.
Main Results:
- Cholinergic therapy (e.g., tacrine) shows modest effects in a subset of AD patients (20-50%).
- Potential predictors of response include psychometric tests, orthostatic blood pressure, pupillary dilation, EEG, CSF neurochemistry, and functional imaging.
- Current findings are promising but limited by small study sizes and open-label designs.
Conclusions:
- Adequate dosing to achieve therapeutic plasma levels is essential before determining non-response.
- Further research with larger, well-designed studies is needed to validate response predictors.
- Personalized approaches are necessary to optimize cholinergic therapy for Alzheimer disease patients.